- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00679458
Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine
January 6, 2010 updated by: University of California, Los Angeles
A Randomized, Double-blind, Cross-over Trial Comparing the Analgesic Potency and Side Effects of Buprenorphine and Ultra-low-dose Naloxone to Buprenorphine Alone
This study compares two medications for analgesic potency and side effects in a sample of individuals with moderate pain.
After screening, eligible participants will be randomly assigned to begin blinded treatment with one of two medications.
Participants receive 5 daily doses of medication (no more than 2 days between each dose) followed by crossover to the opposite treatment condition for 5 additional daily doses.
Each study day, participants will provide a daily pain assessment, receive administration of study medication, and will then be monitored and assessed for pain and side effects over 6 hours.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Treatment of chronic pain typically relies on the effectiveness of opioid analgesics, however, side effects and the potential for users to develop tolerance and addiction may make physicians hesitant to prescribe them.
The development of opioid analgesics with fewer side effects and decreased potential tolerance and addiction would increase the ability to safely and effectively treat pain.
This study will determine whether the addition of an ultra-low dose of naloxone, an opioid antagonist, to buprenorphine, an opioid analgesic pain medication, increases the analgesic potency and reduces side effects compared to buprenorphine alone.
Low doses of naloxone added to buprenorphine have been shown to increase the potency and reduce the side effects of buprenorphine in animal studies and in a human study with healthy volunteers.
The current study aims to extend these findings by assessing the analgesic potency and side effects of a 15:1 ratio of buprenorphine to naloxone in a sample of 12 outpatient participants with moderate pain (4 or greater pain intensity) who are experienced with opioid analgesics.
Participants will be randomly assigned to begin blinded treatment starting with one of two medication regimens: IV buprenorphine + ultra-low-dose naloxone or IV buprenorphine alone.
Participants receive 5 daily doses of medication (no more than 2 days between each dose) followed by crossover to the opposite treatment condition for 5 additional daily doses.
Each study day, participants will provide a daily pain assessment, receive administration of study medication, and will then be monitored and assessed for pain and side effects over the next six hours.
Outcomes for the study include: (1) pain intensity as measured using the Brief Pain Inventory, pain intensity numerical rating scale, and the Beck Depression Inventory, and (2) self-reported side effects/adverse events.
After completion of study participation, participants will resume pre-study pain treatments with their own physician.
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90025'
- UCLA Integrated Substance Abuse Programs Outpatient Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Participants must meet all of the following:
- 18 years of age or older
- Have chronic pain that is not related to cancer, defined as pain expected to last a month or more,(i.e. musculoskeletal pain or neuropathic pain)
- Report pain of moderate to moderately-severe intensity during the week prior to the baseline screening visit (a score greater than or equal to 4 for average pain in the past week on the 0-10 point Pain Intensity-Numerical Rating Scale)
- Have used prescription opioid and/or non-opioid analgesics for the pain on at least 15 of the 30 days prior to the initial baseline/screening visit and have clearance from their prescribing physician to discontinue all non-study-related opiates during study participation
- Willing and able to comply with study procedures
- Willing and able to provide written consent
- If female, not pregnant or lactating and willing to use an acceptable method of birth control (e.g., condoms, IUD, birth control pills, or Depo-Provera)
Exclusion Criteria:
Participants must not meet any of the following:
- Have a history of dependence on opiates, stimulants, alcohol, or benzodiazepines, as defined by DSM-IV criteria, within the past year (physical dependence on prescribed opioid analgesics is allowed but opioid dependence according to DSM-IV, i.e. opioid addiction, is not)
- Use of any illicit or recreational drugs (heroin, cocaine, methamphetamine, marijuana, etc.) ; or use of any long-acting opioid (i.e., methadone) in the 30 days prior to the initial screening visit
- Concomitant use of medications that are inhibitors of CYP3A4 (e.g., azole antifungals, macrolide antibiotics, and HIV protease inhibitors), or medications that induce CYP3A4 activity (e.g., anticonvulsants and rifampin) that may alter the metabolism of buprenorphine
- Have a medical condition that, in the study physician's judgment, may interfere with safe study participation for the individual study candidate. Because medical conditions may differ in terms of safe participation on an individual basis, this criterion must be based on a physician's determination after a medical history, exam, and lab tests and may also involve consultation with a study candidate's primacy care physician. Some examples of medical conditions that may be exclusionary for a particular individual, however include active tuberculosis, unstable and/or significant cardiovascular or liver disease, unstable diabetes (i.e., glycosylated hemoglobin A1C of 12%), uncontrolled HIV infection, altered renal function (serum creatinine males and females:>3x upper limit of normal) or clinically significant elevated liver enzymes (ALT or AST greater than 3x the upper limit of normal)
- Have a current neurological disorder (e.g., organic brain disease, dementia) or current major psychiatric disorder (e.g., schizophrenia, bipolar illness, or PTSD) that would make study agent compliance difficult, that would compromise informed consent, or that would jeopardize safety
- Have a history of suicide attempts in the past 180 days and/or current serious suicidal risk
- Have any history of a seizure disorder
- Have a known allergy or sensitivity to buprenorphine or naloxone
- Receiving long-acting opioids, such as methadone, LAAM, or sustained release morphine, for treatment of pain (due to problems with initiating buprenorphine treatment among patients receiving long-acting opioids)
- Have recent surgery or a major medical procedure that could potentially interfere with study participation
- Any other circumstances that, in the opinion of the investigators, would interfere with study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1.
Study drug: buprenorphine and ultra-low-dose naloxone
|
each participant will be randomly assigned to order of study drug administration in a double-blind manner.
Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days.
Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria.
Medication will be administered IV, and assessments will continue for 6 hours after administration.
Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
|
Active Comparator: 2.
Study drug: buprenorphine
|
each participant will be randomly assigned to order of study drug administration in a double-blind manner.
Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days.
Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria.
Medication will be administered IV, and assessments will continue for 6 hours after administration.
Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain intensity
Time Frame: After each dose of study drug
|
After each dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Self-reported side effects/adverse events
Time Frame: after each daily dose of study drug
|
after each daily dose of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (Actual)
November 1, 2009
Study Completion (Actual)
November 1, 2009
Study Registration Dates
First Submitted
May 14, 2008
First Submitted That Met QC Criteria
May 15, 2008
First Posted (Estimate)
May 16, 2008
Study Record Updates
Last Update Posted (Estimate)
January 7, 2010
Last Update Submitted That Met QC Criteria
January 6, 2010
Last Verified
November 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-06-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
Clinical Trials on buprenorphine and low-dose naloxone
-
Wayne State UniversityCompletedEffects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)Heroin Dependence | Opioid Use DisorderUnited States
-
New York State Psychiatric InstituteSchering-PloughCompleted
-
Paolo MannelliAlkermes, Inc.CompletedLow Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (BUP/NXT-VIVI)Opiate DependenceUnited States
-
VA Office of Research and DevelopmentTerminated
-
State University of New York at BuffaloWithdrawnOpiate AddictionUnited States
-
Duke UniversityNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompletedOpioid Use DisorderUnited States
-
Montefiore Medical CenterRecruiting
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedOpiate DependenceUnited States
-
INSYS Therapeutics IncCompletedStudy of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy VolunteersOpiate DependenceUnited States